NKULHZHYGMZDQP-RHNCMZPLSA-N
C27H23Cl2F5N4O4 — CID 118383631
Data last refreshed: (MolForge compound catalog, from PubChem)
About NKULHZHYGMZDQP-RHNCMZPLSA-N
NKULHZHYGMZDQP-RHNCMZPLSA-N (PubChem CID 118383631) has the molecular formula C27H23Cl2F5N4O4 and a molecular weight of 633.40 g/mol. Its IUPAC name is 4-[4-[[2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl]-[(3,5-difluorophenyl)methyl]carbamoyl]-5-(trifluoromethyl)pyrazol-1-yl]cyclohexane-1-carboxylic acid.
Molecular Properties
| Compound Name | NKULHZHYGMZDQP-RHNCMZPLSA-N |
|---|---|
| PubChem CID | 118383631 |
| Molecular Formula | C27H23Cl2F5N4O4 |
| Molecular Weight | 633.40 g/mol |
| Exact Mass | 632.10 |
| IUPAC Name | 4-[4-[[2-(2,4-dichloro-6-methyl-3-pyridinyl)-2-oxoethyl]-[(3,5-difluorophenyl)methyl]carbamoyl]-5-(trifluoromethyl)pyrazol-1-yl]cyclohexane-1-carboxylic acid |
| SMILES | Cc1cc(Cl)c(C(=O)CN(Cc2cc(F)cc(F)c2)C(=O)c2cnn(C3CCC(C(=O)O)CC3)c2C(F)(F)F)c(Cl)n1 |
| InChI | InChI=1S/C27H23Cl2F5N4O4/c1-13-6-20(28)22(24(29)36-13)21(39)12-37(11-14-7-16(30)9-17(31)8-14)25(40)19-10-35-38(23(19)27(32,33)34)18-4-2-15(3-5-18)26(41)42/h6-10,15,18H,2-5,11-12H2,1H3,(H,41,42) |
| InChIKey | NKULHZHYGMZDQP-UHFFFAOYSA-N |
| XLogP | 6.53 |
| TPSA | 105.39 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 42 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 633.40 |
| LogP ≤ 5 | 6.53 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': '2-halo_pyridine', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118383631 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.